Key Research in Axial Spondyloarthritis Encapsulated

These are interesting and, perhaps, unexpected findings that can be considered in choosing therapies for axSpA. Gastrointestinal side effects and the effects of NSAIDs in older patients and those with cardiovascular risk factors remain important concerns. Still, the data are valuable in assessing benefits and risks of the ever-increasing number of agents for axSpA.   

David S. Pisetsky, MD, PhD, is a professor of medicine and immunology at Duke University School of Medicine, Durham, N.C., and a staff rheumatologist at the Durham VA Medical Center. He also served as the first physician editor of The Rheumatologist.

References

1. Coates L, Selmi C, Mease P, et al. Sex-related differences in baseline patient and disease characteristics: Post hoc analyses of three phase 3, randomized, double-blind, placebo-controlled studies in patients with active psoriatic arthritis [abstract]. Arthritis Rheumatol. 2024;76(suppl 9).
2. Puche-Larrubia M, Ladehesa-Pineda M, Font P, et al. Clinical expression of radiographic axial spondyloarthritis and its association with HLA-B27 in European and Ibero-American populations: Data from the REGISPONSER and RESPONDIA registries [abstract]. Arthritis Rheumatol. 2024;76(suppl 9).
3. Chaudhary H, Pamuk O, Abi Doumeth S, et al. Sex-related differences in efficacy of biologics in axial spondyloarthritis: A systematic review and meta-analysis [abstract]. Arthritis Rheumatol. 2024;76(suppl 9).

4. Mauro D, Vecellio M, Bergot A, et al. Unveiling the uterine-joint axis: Dysbiosis and subclinical uterine inflammation in female axial spondyloarthritis pathogenesis [abstract]. Arthritis Rheumatol. 2024;76(suppl 9).
5. Lichaa A, KRUG P, Nzeusseu Toukap A. Low vitamin D serum level is a risk factor for ankylosis in axial spondyloarthritis: Evidence from a nested-case-control study [abstract]. Arthritis Rheumatol. 2024;76(suppl 9).
6. Talukdar A, Ibeh N, Machhar R, et al. Cellular immune activation signatures at baseline predict response to TNF inhibitors in axial spondyloarthritis [abstract]. Arthritis Rheumatol. 2024;76(suppl 9).
7. Brink A, Mogard E, Lindqvist E, et al. Axial spondyloarthritis patients with comorbid fibromyalgia feel worse, work less and more often try multiple biological DMARDs—Results from a population-based cohort [abstract]. Arthritis Rheumatol. 2024;76(suppl 9).
8. Bento da Silva A, Ramiro S, van Lunteren M, et al. A two-year comparison of spinal and hip mobility between axial spondyloarthritis and chronic back pain patients in the spondyloarthritis caught early (SPACE) cohort [abstract]. Arthritis Rheumatol. 2024;76(suppl 9).
9. Franc M, Guibourdenche J, Tournadre A, Molto A. AMH titers in women with axial spondyloarthritis are significantly lower compared to the general population: An analysis of the 10-year follow-up of the DESIR cohort [abstract]. Arthritis Rheumatol. 2024;76(suppl 9).
10. Meade Aguilar J, Liew J, Stovall R, et al. Nonsteroidal anti-inflammatory drug use and incident hypertension among patients with axial spondyloarthritis [abstract]. Arthritis Rheumatol. 2024;76(suppl 9).